Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped down prior to trading on Thursday after an insider sold shares in the company. The stock had previously closed at $26.95, but opened at $25.16. Hims & Hers Health shares last traded at $26.27, with a volume of 6,054,360 shares traded.

Specifically, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $28.50, for a total value of $330,058.50. Following the transaction, the chief financial officer now owns 118,960 shares in the company, valued at approximately $3,390,360. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 3,236 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $28.72, for a total transaction of $92,937.92. Following the completion of the sale, the insider now directly owns 162,898 shares of the company’s stock, valued at $4,678,430.56. The trade was a 1.95 % decrease in their position. The disclosure for this sale can be found here. In related news, insider Soleil Boughton sold 4,151 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14. Following the completion of the sale, the insider now directly owns 166,134 shares of the company’s stock, valued at approximately $7,499,288.76. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Analyst Ratings Changes

HIMS has been the topic of a number of recent research reports. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Truist Financial reduced their price target on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Finally, BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $38.25.

Hims & Hers Health Stock Performance

The stock has a market cap of $6.05 billion, a price-to-earnings ratio of 61.91 and a beta of 1.65. The business’s 50 day moving average is $37.26 and its 200 day moving average is $30.61.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently bought and sold shares of the stock. Means Investment CO. Inc. grew its stake in Hims & Hers Health by 23.5% in the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock valued at $1,210,000 after buying an additional 9,508 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock valued at $5,349,000 after acquiring an additional 146,621 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $2,628,000. Pacer Advisors Inc. bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $374,000. Finally, Genesee Capital Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth about $889,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.